These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31462106)

  • 21. Alkaptonuria: a very rare metabolic disorder.
    Aquaron R
    Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ApreciseKUre: an approach of Precision Medicine in a Rare Disease.
    Spiga O; Cicaloni V; Bernini A; Zatkova A; Santucci A
    BMC Med Inform Decis Mak; 2017 Apr; 17(1):42. PubMed ID: 28410607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms involved in the unbalanced redox homeostasis in osteoblastic cellular model of Alkaptonuria.
    Schiavone ML; Pecorelli A; Woodby B; Ferrara F; Pambianchi E; Santucci A; Valacchi G
    Arch Biochem Biophys; 2020 Sep; 690():108416. PubMed ID: 32502471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homogentisic acid induces morphological and mechanical aberration of ochronotic cartilage in alkaptonuria.
    Bernardini G; Leone G; Millucci L; Consumi M; Braconi D; Spiga O; Galderisi S; Marzocchi B; Viti C; Giorgetti G; Lupetti P; Magnani A; Santucci A
    J Cell Physiol; 2019 May; 234(5):6696-6708. PubMed ID: 30341892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Redox proteomics gives insights into the role of oxidative stress in alkaptonuria.
    Braconi D; Millucci L; Ghezzi L; Santucci A
    Expert Rev Proteomics; 2013 Dec; 10(6):521-35. PubMed ID: 24206226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of 11 Novel Homogentisate 1,2 Dioxygenase Variants in Alkaptonuria Patients and Establishment of a Novel LOVD-Based HGD Mutation Database.
    Zatkova A; Sedlackova T; Radvansky J; Polakova H; Nemethova M; Aquaron R; Dursun I; Usher JL; Kadasi L
    JIMD Rep; 2012; 4():55-65. PubMed ID: 23430897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
    Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
    Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of Enhanced Osteoclastogenesis in Alkaptonuria.
    Brunetti G; Tummolo A; D'Amato G; Gaeta A; Ortolani F; Piacente L; Giordano P; Colucci S; Grano M; Papadia F; Faienza MF
    Am J Pathol; 2018 Apr; 188(4):1059-1068. PubMed ID: 29353057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative proteomics in alkaptonuria provides insights into inflammation and oxidative stress.
    Braconi D; Bernardini G; Paffetti A; Millucci L; Geminiani M; Laschi M; Frediani B; Marzocchi B; Santucci A
    Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):271-280. PubMed ID: 27590860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
    J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.
    Tinti L; Spreafico A; Braconi D; Millucci L; Bernardini G; Chellini F; Cavallo G; Selvi E; Galeazzi M; Marcolongo R; Gallagher JA; Santucci A
    J Cell Physiol; 2010 Oct; 225(1):84-91. PubMed ID: 20648626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing.
    Taylor AM; Hsueh MF; Ranganath LR; Gallagher JA; Dillon JP; Huebner JL; Catterall JB; Kraus VB
    Rheumatology (Oxford); 2017 Jan; 56(1):156-164. PubMed ID: 28028161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on 'black bone disease' in Italy.
    Nemethova M; Radvanszky J; Kadasi L; Ascher DB; Pires DE; Blundell TL; Porfirio B; Mannoni A; Santucci A; Milucci L; Sestini S; Biolcati G; Sorge F; Aurizi C; Aquaron R; Alsbou M; Lourenço CM; Ramadevi K; Ranganath LR; Gallagher JA; van Kan C; Hall AK; Olsson B; Sireau N; Ayoob H; Timmis OG; Sang KH; Genovese F; Imrich R; Rovensky J; Srinivasaraghavan R; Bharadwaj SK; Spiegel R; Zatkova A
    Eur J Hum Genet; 2016 Jan; 24(1):66-72. PubMed ID: 25804398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alkaptonuria.
    Mistry JB; Bukhari M; Taylor AM
    Rare Dis; 2013; 1():e27475. PubMed ID: 25003018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homogentisic acid induces cytoskeleton and extracellular matrix alteration in alkaptonuric cartilage.
    Galderisi S; Cicaloni V; Milella MS; Millucci L; Geminiani M; Salvini L; Tinti L; Tinti C; Vieira OV; Alves LS; Crevenna AH; Spiga O; Santucci A
    J Cell Physiol; 2021 Aug; 236(8):6011-6024. PubMed ID: 33469937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homogentisic acid affects human osteoblastic functionality by oxidative stress and alteration of the Wnt/β-catenin signaling pathway.
    Schiavone ML; Millucci L; Bernardini G; Giustarini D; Rossi R; Marzocchi B; Santucci A
    J Cell Physiol; 2020 Oct; 235(10):6808-6816. PubMed ID: 31989660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoothened-antagonists reverse homogentisic acid-induced alterations of Hedgehog signaling and primary cilium length in alkaptonuria.
    Gambassi S; Geminiani M; Thorpe SD; Bernardini G; Millucci L; Braconi D; Orlandini M; Thompson CL; Petricci E; Manetti F; Taddei M; Knight MM; Santucci A
    J Cell Physiol; 2017 Nov; 232(11):3103-3111. PubMed ID: 28019670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacterial quality of urinary tract in patients with alkaptonuria.
    Al-Tarawneh A; Al-Limoun M; Khlaifat AM; Tarawneh I; Mwafi N; Khleifat K; Alqaraleh M; Mizher H
    Am J Med Sci; 2023 Apr; 365(4):368-374. PubMed ID: 36608845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.